Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.
Despite advancements in targeted therapies and immune checkpoint inhibitors, many patients with advanced NSCLC experience disease progression, necessitating novel therapeutic approaches like antibody-drug conjugate (ADC).
